利司那肽在2型糖尿病个体化治疗中的应用

Individualized, patient-centered use of lixisenatide for the treatment of type 2 diabetes mellitus

在分析了胃排空和胃排空时胰升糖素样肽1（GLP-1）释放的生理学基础后,本文着重讨论了短效GLP-1受体激动剂,如利司那肽对2型糖尿病患者的疗效和安全性,以及GLP-1受体激动剂的心血管效应.在获得《Expert Opinion on Drug Metabolism＆Toxicology》杂志（Taylor＆Francis Group）授权同意后,本文对2017年3月发表于该刊上的综述＂利司那肽在2型糖尿病个体化治疗中的应用＂进行中文编译.

discussed the role of gastric emptying and its related glucagon-like peptide-1（GLP-1） releasing in maintaining glucose homeostasis, and further illustrated the efficacy and safety of short-acting GLP-1 receptor agonists（ GLP-1 RAs） ,such as Lixisenatide in treating type 2 diabetes. The cardiovascular effects of GLP-1 RAs were also reviewed. This article is the Chinese translation of ＂Individualized, patient-centered use of lixisenatide for the treatment of type 2 diabetes mellitus＂[Expert Opin Drug Metab Toxicol, 2017,13（3）：311-321]which was published in March 2017, with the permission from the journal（Taylor＆Francis Group）.